Copyright
©The Author(s) 2024.
World J Crit Care Med. Sep 9, 2024; 13(3): 96882
Published online Sep 9, 2024. doi: 10.5492/wjccm.v13.i3.96882
Published online Sep 9, 2024. doi: 10.5492/wjccm.v13.i3.96882
Risk factor | Adjusted odds ratio (95%CI) | P value |
Age | 1.21 (1.06-1.39) | 0.005a |
Sex | - | 0.742 |
Diabetes | - | 0.057 |
Ischemic heart disease | - | 0.686 |
Duration of antihypertensive therapy | 0.69 (0.51-0.94) | 0.008a |
ACEI/ARB | - | 0.997 |
Calcium channel blockers | - | 0.996 |
ACEI/ARB + calcium channel blockers | - | 0.997 |
Beta-blockers | - | 0.998 |
Hemoglobin | - | 0.465 |
Neutrophil/lymphocyte ratio | - | 0.071 |
ESR | 0.92 (0.87-0.97) | 0.005a |
hs-CRP | 0.97 (0.95-0.99) | 0.014a |
Blood urea | 0.095 | |
Serum ferritin | - | 0.081 |
Serum interleukin 6 | 0.97 (0.96-0.99) | 0.009a |
- Citation: Varatharajan S, Bohra GK, Bhatia PK, Khichar S, Meena M, Palanisamy N, Gaur A, Garg MK. Outcome of COVID-19 infection in patients on antihypertensives: A cross-sectional study. World J Crit Care Med 2024; 13(3): 96882
- URL: https://www.wjgnet.com/2220-3141/full/v13/i3/96882.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v13.i3.96882